Evaluation of The Effect of Bupivacaine (Marcaine) in Reducing Early Post Tonsillectomy Pain

NCT ID: NCT01582022

Last Updated: 2012-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research Methodology:

It will be a prospective, randomized, placebo-controlled, single-blind, intra-individual study in which one tonsillar fossa will be the tested side, and the other fossa will be the control. And the tested side will be packed with bupivacaine for five minutes. In the other hand, the controlled side will be packed for five minutes with gauze soaked in normal saline. The selection of the tested side and controlled side will be randomized based on the last digit in the medical record number (i.e. if the last digit is even then the tested side is the right and if the last digit is odd then the tested side is the left). Pain evaluation will be by visual analog scale and it will be in frequency of 2, 4, 6, 8, 12, 24 hours post-op.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluation of The Effect of Bupivacaine (marcaine) in Reducing Early Post Tonsillectomy Pain (Prospective, randomized, intra-individual study.) Study guidelines

Aim of the study

\- to evaluate the effectiveness of applying bupivacaine intra-operative in reducing early post-tonsillectomy pain

Patients and methods

* It will be a randomized, placebo-controlled, single-blinded study
* one tonsillar fossa will be the tested side, and the other fossa will be the control
* to insure the random selection, the tested and control sides will be selected based on unpredicted method e.g. based on the last number in pt MRN: If the last # is even (0, 2, 4, 6, 8) = right side will be the tested If the last # is odd (1, 3, 5, 7, 9) = left side will be the tested
* Exclusion criteria included :

1. pt with past history of unilateral peritonsillar abscess
2. the current, regular use of a systemic steroid or NSAID
3. a known hypersensitivity to bupivacaine
4. a combined with unilateral myringotomy or bilateral myringotomy with unilateral ventilation tube
5. pt with poor dental hygiene
* accompanied adenoidectomy is not an exclusion criteria
* the tested side will be : packed (after classic tonsillectomy) with gauze soaked in 0.5% bupivacaine, (2ml of bupivacaine + 2ml NS)for 5 min.
* the control side will undergoing the same of tested side but with normal saline
* post-operative analgesia will be paracetamol
* pain evaluation will be by visual analog scale (fig. 1) and it will be in frequency of 2, 4, 6, 8, 12, 24 hours post-op (frequency can be re-adjusted)
* Data of pain will be collected by the nurse. And they will not know which side is the tested. (single- blind)
* after phase I (data collection). Data will be calculated for P-value and other statistics scores
* Targeted sample size is 35 patients.
* patients will be consented for the possible adverse reactions of local application of the tested medicine (e.g. allergic reactions, Paresthesia). However, because in our study we will not add adrenaline, so differences in incidence of post-tonsillectomy bleeding is not expected.
* data will be statistically analyzed by McNemar's test
* For the data safety monitoring of the study, an independent external otolaryngology consultant (Dr.Ahmed Alarfij) will be assigned to monitor the safety of study participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tonsillectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

local anesthetic

local anesthetic agent

Group Type EXPERIMENTAL

Bupivacaine

Intervention Type DRUG

local application for 5 minutes

normal saline

comparator

Group Type PLACEBO_COMPARATOR

normal saline

Intervention Type DRUG

local application for 5 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine

local application for 5 minutes

Intervention Type DRUG

normal saline

local application for 5 minutes

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

marcaine comparator

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patients undergoing tonsillectomy

Exclusion Criteria

1. pt with past history of unilateral peritonsillar abscess
2. the current, regular use of a systemic steroid or NSAID
3. a known hypersensitivity to bupivacaine
4. a combined with unilateral myringotomy or bilateral myringotomy with unilateral ventilation tube
5. pt with poor dental hygiene
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King Saud University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Abdulmalik S. Alsaied

otolaryngology specialist

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

abdulmalik s alsaied, sborl

Role: CONTACT

00966504808705

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-12-598

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.